Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

iseases, including SJIA[5]. ACZ885 works by neutralizing IL-1 beta for a sustained period of time, therefore inhibiting inflammation.

ACZ885 is currently approved in the US and other countries for a different disease state.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "can," "on track," "potentially," "will," "planned," "may," "committed," "potential," or similar expressions, or by express or implied discussions regarding potential new indications or labeling for ACZ885 or regarding potential future revenues from ACZ885. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with ACZ885 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that ACZ885 will be submitted or approved for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that ACZ885 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding ACZ885 could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; unexpected manufacturing issues, the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... a meter in size, are around us every day. ... as in some innovative early cancer treatments, but they ... traffic emissions, cosmetics, sunscreen and electronics. , A team ... by Lan Yang, PhD, the Das Family Career Development ... collaborators at Tsinghua University in China have developed a ...
(Date:9/2/2014)... September 02, 2014 Press attending the ... to take advantage of the people and events in ... below are available throughout the day. Additionally, we will ... POET and DSM representatives as well as representatives from ... is appreciated. , Please remember to RSVP to ...
(Date:9/2/2014)... -- Technology Applications International Corporation (the "Company" or "NUUU")(OTC BB: ... Inc. has signed an additional exclusive licensing agreement with ... Johnson Space Center in Houston , ... Charles J. Scimeca , NUUU,s ... latest, exclusive agreement with NASA. In addition to our ...
(Date:9/2/2014)... Sept. 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Patent and Trademark Office (PTO) has issued a patent ... for weight loss. NB32 is a fixed-dose combination of ... U.S. Patent No. 8,815,889 claims methods for treating insulin ... patent expires in 2024. If NB32 is approved for ...
Breaking Biology Technology:Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... AC Immune SA, a leader,in Alzheimer,s disease drug development, ... Immune as Technology Pioneer 2009 for its,accomplishments as an ... a deep impact on business and society. , ... that it has reached significant clinical,milestones in the development ...
... A 60-year-old,prostate cancer patient from Montpellier has become ... RapidArc(TM) technology from Varian Medical Systems,(NYSE: ... intensity modulated radiotherapy,(IMRT). Each of his treatments at ... city took just 75 seconds, several times faster ...
... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it ... year 2009 on December 10, 2008 at 7:00 a.m. EST and ... at 11:30 a.m. EST on the same day. , ... results for the second quarter ended October 31, 2008 and will ...
Cached Biology Technology:Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development 2Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 2Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 3Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results 2
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... the University of Warwick in the UK and the ... Journal Early Human Development , has found that ... birth and the use of mechanical ventilation are key ... Mathematic abilities are crucial for lifelong academic attainment. Impairments ... Earlier studies of children who are born very preterm ...
(Date:9/2/2014)... the most ideal source of nutrition for infants ... in the evolution and civilizations of human beings. ... large number of bacterial species, including some opportunistic ... surprise to scientists and physicians. , Indeed, the ... the result of co-evolutionary and co-adaptive interactions between ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Mechanical ventilation a key indicator for pre-term children's math problems 2Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3
... on labor-intensive microscopic examination, using century-old cell-staining ... and may give false readings. , A ... Laboratories researcher Paul Gourley, has provided laboratory ... liver tumor cells at their earliest stages, ...
... Canadian Network for Vaccines and Immunotherapeutics, has announced,the ... well the thymus (an organ,located at the base ... a,functional abnormality of this organ in HIV-infected individuals. ... professor at,Université de Montréal, scientist at the CHUM ...
... used to synthesize plastic food containers has been ... of prostate cancer cell,potentially affecting the treatment efficacy ... published in the January 1 issue of Cancer,Research, ... to,exposure to the chemical BPA (bisophenol A), an ...
Cached Biology News:Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells 2Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells 3Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells 2
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
... Neogens enzyme-linked immunosorbent assay (ELISA) ... as screening devices for the detection of ... The kits are intended for forensic use ... samples be confirmed by a quantitative method ...
... SUPERaseIn RNase Inhibitor (patent pending) is ... that noncovalently binds and inhibits the most ... B, C, 1 and T1. SUPERaseIn can ... contamination could be problematic. It is ideal ...
Biology Products: